NCT01357148终止不适用
Sitagliptin Phosphate/Metformin HCl (JANUMET®) Post Marketing Surveillance Protocol
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 143
- 主要终点
- Number of Participants With an Adverse Event
研究概览
简要总结
The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be taking sitagliptin phosphate/metformin HCl (JANUMET®) for the treatment of type 2 diabetes mellitus
- •Treating physician must agree to provide information regarding the participant's treatment
排除标准
- 未提供
研究组 & 干预措施
Participants treated with sitagliptin phosphate/metformin HCl
干预措施: Sitagliptin Phosphate/Metformin HCl (JANUMET®) (Drug)
结局指标
主要结局
Number of Participants With an Adverse Event
时间窗: Up to approximately 28 months
Number of Participants With Concomitant Conditions
时间窗: Up to approximately 28 months
Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl
时间窗: Up to approximately 28 months
Number of Participants Taking Concomitant Medications
时间窗: Up to approximately 28 months
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
The Role of P-glycoprotein in Sitagliptin Clinical PharmacologyHealthyNCT01112670University of Colorado, Denver33
Enrolling By Invitation
2 期
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC PatientsPDAC - Pancreatic Ductal AdenocarcinomaNCT05947825Tianjin Medical University Cancer Institute and Hospital30
已完成
4 期
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01269996Chinese University of Hong Kong71
已完成
2 期
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)Type 2 Diabetes MellitusNCT00127192Merck Sharp & Dohme LLC363
已完成
4 期
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)Type 2 Diabetes MellitusNCT00993187Merck Sharp & Dohme LLC292